<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603809</url>
  </required_header>
  <id_info>
    <org_study_id>AC-080A201</org_study_id>
    <nct_id>NCT02603809</nct_id>
  </id_info>
  <brief_title>Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on
      diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.

      Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood
      pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood
      pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral
      regimen of 4 doses of ACT-132577.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation in the study is planned to last up to 18 weeks. A single-blind placebo run-in
      period of 4 to 6 weeks after which participants will be randomized into a double-blind
      treatment period of 8 weeks and a washout and follow-up period ending with an end-of-study
      visit approximately 12 weeks after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2015</start_date>
  <completion_date type="Actual">April 7, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</measure>
    <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough</measure>
    <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure</measure>
    <time_frame>End of double-blind treatment (Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported.
The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
    <description>Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged.
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
    <description>Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group.
The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5).
The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1).
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</measure>
    <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
    <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1659</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprocitentan 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprocitentan 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprocitentan 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprocitentan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 5 mg</intervention_name>
    <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
    <arm_group_label>Aprocitentan 5 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 10 mg</intervention_name>
    <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
    <arm_group_label>Aprocitentan 10 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 25 mg</intervention_name>
    <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
    <arm_group_label>Aprocitentan 25 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 50 mg</intervention_name>
    <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
    <arm_group_label>Aprocitentan 50 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril 20 mg</intervention_name>
    <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan</description>
    <arm_group_label>Lisinopril 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  No contra-indication to stop (according to label) anti-hypertensive treatment(s) at
             screening

          -  Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive
             treatment(s):

             -- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to &lt; 110
             mmHg measured by office blood pressure measurements (OBPM).

          -  Women of childbearing potential must have a negative pregnancy test and use of
             reliable methods of contraception

        Exclusion Criteria:

          -  Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP;
             measured by OBPM) ≥ 180/110 mmHg, respectively.

          -  Secondary hypertension

          -  Known hypertensive retinopathy greater than Keith-Wagener Grade 2

          -  Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary
             artery bypass graft within 12 months prior to randomization

          -  Unstable angina within 6 months prior to randomization

          -  Heart failure New York Heart Association class III and IV

          -  Valvular defects (such as severe aortic or mitral valve disease) and/or
             hemodynamically relevant rhythm disturbances

          -  Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident
             within 6 months prior to randomization.

          -  Subjects working night shifts

          -  Body mass index &lt; 20 kg/m2 or &gt; 40 kg/m2

          -  Treatment with any medication which may affect BP (e.g., treatment of psychiatric
             diseases, ophthalmic preparations)

          -  Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers

          -  Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1
             month prior to Screening (Visit 1)

          -  Treatment with another investigational treatment within 1 month prior to Screening
             (Visit 1)

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ClinicalTrials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Appalachian Cardiovascular Associates</name>
      <address>
        <city>Fort Payne</city>
        <state>Alabama</state>
        <zip>35967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Family Practice / Radiant Research Inc</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research Institute LLC</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Arizona Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Clinical Research LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sun Clinical Research LLc</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Physician Network Clinical Research Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Center for Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entertainment Medical Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Research Medical Clinic / Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting LLC</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfieri Cardiology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC - Cardiology</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida INC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan Graff, MD, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canvas Clinical Research, LLC</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute, INC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clin Res CTR</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associated LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates, LLC</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trials LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research - Nola</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinsite LLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primecare Research Associates, LLC</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. / Diagnostic Center Of Medicine - Durango</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine/Internal Medicine Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmquest LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27604-1547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Clinic - Edmond / Radiant Research Inc</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. / Oklahoma City Clinic - Midwest City</name>
      <address>
        <city>Midwest City</city>
        <state>Oklahoma</state>
        <zip>73110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Clinical Studies</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detweiler Family Medicine and Associates PC</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Research Center</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Degarmo Institute of Medical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Hypertension &amp; Metabolic Research Institute</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas - ACRC Trials</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TR - Global Medical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigations of Texas</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates LLC</name>
      <address>
        <city>Port Arthur</city>
        <state>Texas</state>
        <zip>77640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bandera Family Health Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onwards Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Levis</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Montreal Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2Y 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Montreal Inc</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2Y 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Pointe Claire</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Reserach Sherbrooke Inc</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Department Barzilai</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Hospital - Hypertension Unit</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hyper Unit, Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hypertension Treatment Center, Internal Dep, Hadassah</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hypertension And Nephrology Department, Meir Medical Center</name>
      <address>
        <city>Kefar Sava</city>
        <zip>44261</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Med Department A, Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Concepts, PSC</name>
      <address>
        <city>Cidra</city>
        <zip>00739</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research &amp; Cardiovascular Corp.</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <results_first_submitted>February 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <disposition_first_submitted>March 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 29, 2018</disposition_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02603809/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02603809/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 99 sites in 3 countries. Of the 1659 participants that signed the informed consent 996 entered the run-in period (i.e. 663 participants were screening failures: 651 failed to meet the eligibility criteria to enter the run-in period, 6 withdrew and 6 did not enter the run-in period for other reasons).</recruitment_details>
      <pre_assignment_details>Of the 996 participants enrolled into the run-in period, a total 992 participants received at least one dose of the single-blind placebo. Of these 992 participants 502 were considered run-in failures (390 failing to meet randomization criteria, 57 withdrew consent and 55 left for other reasons) and 490 participants were randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="P2">
          <title>Aprocitentan 5 mg</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received 5 mg aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>Aprocitentan 10 mg</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>Aprocitentan 25 mg</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="P5">
          <title>Aprocitentan 50 mg</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="P6">
          <title>Lisinopril 20 mg</title>
          <description>After a 4 to 6-week single-blind placebo run-in period, participants received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="81"/>
                <participants group_id="P6" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol Set</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Per-Protocol Set</title>
              <participants_list>
                <participants group_id="P1" count="66">One participant had out of analysis window blood pressure measurements.</participants>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-specified discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (N=490), i.e. all participants randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to placebo treatment for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Aprocitentan 5 mg</title>
          <description>Participants randomized to 5 mg aprocitentan treatment for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Aprocitentan 10 mg</title>
          <description>Participants randomized to 10 mg aprocitentan treatment for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Aprocitentan 25 mg</title>
          <description>Participants randomized to 25 mg aprocitentan treatment for 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Aprocitentan 50 mg</title>
          <description>Participants randomized to 50 mg aprocitentan treatment for 8 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Lisinopril 20 mg</title>
          <description>Participants randomized to 20 mg lisinopril treatment for 8 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="81"/>
            <count group_id="B6" value="81"/>
            <count group_id="B7" value="490"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.
In the placebo group, one participant had out of analysis window blood pressure measurement. This participant was part of the PPS but not part of the modified Per Protocol Set (N=409).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="9.1"/>
                    <measurement group_id="B2" value="54.1" spread="8.5"/>
                    <measurement group_id="B3" value="55.3" spread="9.8"/>
                    <measurement group_id="B4" value="55.1" spread="10.0"/>
                    <measurement group_id="B5" value="54.2" spread="9.3"/>
                    <measurement group_id="B6" value="56.0" spread="9.0"/>
                    <measurement group_id="B7" value="54.7" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="9.1"/>
                    <measurement group_id="B2" value="55.0" spread="8.5"/>
                    <measurement group_id="B3" value="55.8" spread="9.5"/>
                    <measurement group_id="B4" value="55.7" spread="9.8"/>
                    <measurement group_id="B5" value="54.0" spread="9.4"/>
                    <measurement group_id="B6" value="56.1" spread="9.4"/>
                    <measurement group_id="B7" value="55.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>modified Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="9.1"/>
                    <measurement group_id="B2" value="55.0" spread="8.5"/>
                    <measurement group_id="B3" value="55.8" spread="9.5"/>
                    <measurement group_id="B4" value="55.7" spread="9.8"/>
                    <measurement group_id="B5" value="54.0" spread="9.4"/>
                    <measurement group_id="B6" value="56.1" spread="9.4"/>
                    <measurement group_id="B7" value="55.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.
In the placebo group, one participant had out of analysis window blood pressure measurement. This participant was part of the PPS but not part of the modified Per Protocol Set (N=409).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>modified Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="71"/>
                    <measurement group_id="B7" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.
In the placebo group, one participant had out of analysis window blood pressure measurement. This participant was part of the PPS but not part of the modified Per Protocol Set (N=409).</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.0" spread="18.9"/>
                    <measurement group_id="B2" value="88.6" spread="16.9"/>
                    <measurement group_id="B3" value="90.1" spread="18.3"/>
                    <measurement group_id="B4" value="91.1" spread="16.9"/>
                    <measurement group_id="B5" value="87.6" spread="15.8"/>
                    <measurement group_id="B6" value="87.0" spread="17.2"/>
                    <measurement group_id="B7" value="89.4" spread="17.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.0" spread="19.2"/>
                    <measurement group_id="B2" value="88.3" spread="17.6"/>
                    <measurement group_id="B3" value="89.3" spread="19.0"/>
                    <measurement group_id="B4" value="91.7" spread="18.1"/>
                    <measurement group_id="B5" value="87.1" spread="15.8"/>
                    <measurement group_id="B6" value="86.5" spread="16.0"/>
                    <measurement group_id="B7" value="89.0" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>modified Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.6" spread="19.0"/>
                    <measurement group_id="B2" value="88.3" spread="17.6"/>
                    <measurement group_id="B3" value="89.3" spread="19.0"/>
                    <measurement group_id="B4" value="91.7" spread="18.1"/>
                    <measurement group_id="B5" value="87.1" spread="15.8"/>
                    <measurement group_id="B6" value="86.5" spread="16.0"/>
                    <measurement group_id="B7" value="89.0" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.
In the placebo group, one participant had out of analysis window blood pressure measurement. This participant was part of the PPS but not part of the modified Per Protocol Set (N=409).</population>
          <units>kilograms per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="5.07"/>
                    <measurement group_id="B2" value="30.1" spread="4.56"/>
                    <measurement group_id="B3" value="30.8" spread="4.52"/>
                    <measurement group_id="B4" value="31.0" spread="4.16"/>
                    <measurement group_id="B5" value="30.2" spread="4.55"/>
                    <measurement group_id="B6" value="30.4" spread="4.59"/>
                    <measurement group_id="B7" value="30.5" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="5.1"/>
                    <measurement group_id="B2" value="29.8" spread="4.5"/>
                    <measurement group_id="B3" value="30.4" spread="4.6"/>
                    <measurement group_id="B4" value="31.0" spread="4.3"/>
                    <measurement group_id="B5" value="30.3" spread="4.7"/>
                    <measurement group_id="B6" value="30.4" spread="4.6"/>
                    <measurement group_id="B7" value="30.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>modified Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="5.1"/>
                    <measurement group_id="B2" value="29.8" spread="4.5"/>
                    <measurement group_id="B3" value="30.4" spread="4.6"/>
                    <measurement group_id="B4" value="31.0" spread="4.3"/>
                    <measurement group_id="B5" value="30.3" spread="4.7"/>
                    <measurement group_id="B6" value="30.4" spread="4.6"/>
                    <measurement group_id="B7" value="30.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of essential hypertension at screening</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.13" spread="8.72"/>
                    <measurement group_id="B2" value="8.12" spread="8.25"/>
                    <measurement group_id="B3" value="10.48" spread="10.18"/>
                    <measurement group_id="B4" value="9.56" spread="8.97"/>
                    <measurement group_id="B5" value="10.60" spread="9.95"/>
                    <measurement group_id="B6" value="11.79" spread="10.47"/>
                    <measurement group_id="B7" value="9.94" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.24" spread="8.93"/>
                    <measurement group_id="B2" value="8.38" spread="8.62"/>
                    <measurement group_id="B3" value="10.6" spread="10.51"/>
                    <measurement group_id="B4" value="9.19" spread="8.61"/>
                    <measurement group_id="B5" value="10.35" spread="10.07"/>
                    <measurement group_id="B6" value="12.53" spread="10.88"/>
                    <measurement group_id="B7" value="10.06" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antihypertensive treatment at screening</title>
          <population>Per Protocol Set (PPS, N=410) 8 weeks in the double-blind period, and no major protocol deviation.
In the placebo group, one participant had out of analysis window blood pressure measurement. This participant was part of the PPS but not part of the modified Per Protocol Set (N=409).</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Full Analysis Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="81"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>modified Per Protocol Set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="67"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="69"/>
                    <count group_id="B7" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
        <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
        <population>Modified Per-protocol set (mPPS). All participants who had a mean trough sitting diastolic blood pressure (SiDBP) at Week-8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
          <population>Modified Per-protocol set (mPPS). All participants who had a mean trough sitting diastolic blood pressure (SiDBP) at Week-8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="5.4"/>
                    <measurement group_id="O2" value="97.8" spread="5.5"/>
                    <measurement group_id="O3" value="97.7" spread="4.3"/>
                    <measurement group_id="O4" value="97.8" spread="4.8"/>
                    <measurement group_id="O5" value="98.2" spread="5.3"/>
                    <measurement group_id="O6" value="96.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="11.1"/>
                    <measurement group_id="O2" value="-6.3" spread="8.9"/>
                    <measurement group_id="O3" value="-9.9" spread="8.7"/>
                    <measurement group_id="O4" value="-12.0" spread="8.2"/>
                    <measurement group_id="O5" value="-10.0" spread="7.9"/>
                    <measurement group_id="O6" value="-8.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Multiple Comparison Procedure-Modeling (MCP-Mod) was used to assess a dose-response across placebo and all aprocitentan doses. The null hypothesis of &quot;no dose-response&quot; was rejected if at least one of the six Multiple Contrast Tests (MCTs) had a multiplicity adjusted p-value &lt;0.05. The analysis was performed using the R-package &quot;DoseFinding&quot; (Bornkamp B, Pinheiro J, Bretz F. Planning and analyzing dose finding experiments. 2016. Available from: cran.r-projects.org/web/packages/DoseFinding.)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Multiple Comparison Procedure-Modeling</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8117</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.10</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.532</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.68</ci_lower_limit>
            <ci_upper_limit>-1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-6.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.554</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.80</ci_lower_limit>
            <ci_upper_limit>-3.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.75</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.</description>
        <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
        <population>Modified Per-protocol set (mPPS). All participants who had a mean trough sitting systolic blood pressure (SiSBP) at Week 8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.</description>
          <population>Modified Per-protocol set (mPPS). All participants who had a mean trough sitting systolic blood pressure (SiSBP) at Week 8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.2" spread="13.1"/>
                    <measurement group_id="O2" value="149.4" spread="13.9"/>
                    <measurement group_id="O3" value="149.8" spread="12.7"/>
                    <measurement group_id="O4" value="151.2" spread="13.7"/>
                    <measurement group_id="O5" value="148.6" spread="12.8"/>
                    <measurement group_id="O6" value="149.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="18.8"/>
                    <measurement group_id="O2" value="-10.3" spread="15.3"/>
                    <measurement group_id="O3" value="-15.0" spread="14.5"/>
                    <measurement group_id="O4" value="-18.5" spread="15.0"/>
                    <measurement group_id="O5" value="-15.1" spread="11.8"/>
                    <measurement group_id="O6" value="-12.8" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Multiple Comparison Procedure-Modeling (MCP-Mod) was used to assess a dose-response across placebo and all aprocitentan doses. The null hypothesis of &quot;no dose-response&quot; was rejected if at least one of the six Multiple Contrasts Tests (MCTs) had a multiplicity adjusted p-value &lt;0.05. The analysis was performed using the R-package &quot;DoseFinding&quot; (Bornkamp B, Pinheiro J, Bretz F. Planning and analyzing dose finding experiments. 2016. Available from: cran-rprojects.org/web/packages/DoseFinding.)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Multiple Comparison Procedure-Modeling</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7071</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.445</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.44</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0138</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-7.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.420</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.98</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-9.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.457</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.92</ci_lower_limit>
            <ci_upper_limit>-3.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-7.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.58</ci_lower_limit>
            <ci_upper_limit>-1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported.
The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.</description>
        <time_frame>End of double-blind treatment (Day 56)</time_frame>
        <population>Modified Per Protocol Set (mPPS). All participants who had diastolic and systolic blood pressure measurements at Week 8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported.
The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.</description>
          <population>Modified Per Protocol Set (mPPS). All participants who had diastolic and systolic blood pressure measurements at Week 8 of the double-blind treatment period and that did not have any major protocol deviation were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SiDBP less than 90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SiDBP less than 85 mmHg (CHEP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SiSBP less than 140 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SiSBP less than 135 mmHg (CHEP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.</description>
        <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
        <population>Modified Per Protocol Set (mPPS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>20 mg
Lisinopril: 20 mg capsules orally o.d. for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.</description>
          <population>Modified Per Protocol Set (mPPS).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.</description>
        <time_frame>Baseline (Day 1) and end of double-blind treatment (Day 56)</time_frame>
        <population>Modified Per Protocol Set (mPPS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.</description>
          <population>Modified Per Protocol Set (mPPS).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)</title>
        <description>Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged.
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
        <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
        <population>All participants in a treatment group with a full set of ABPM (Ambulatory Blood Pressure Monitoring) values over the 24-hour period at baseline and at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)</title>
          <description>Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged.
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
          <population>All participants in a treatment group with a full set of ABPM (Ambulatory Blood Pressure Monitoring) values over the 24-hour period at baseline and at Week 8.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 24-hour mean DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.46" spread="10.66"/>
                    <measurement group_id="O2" value="90.60" spread="10.19"/>
                    <measurement group_id="O3" value="92.60" spread="10.92"/>
                    <measurement group_id="O4" value="89.28" spread="9.53"/>
                    <measurement group_id="O5" value="91.53" spread="10.54"/>
                    <measurement group_id="O6" value="91.18" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change in 24-hour mean DBP at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="5.52"/>
                    <measurement group_id="O2" value="-3.76" spread="6.36"/>
                    <measurement group_id="O3" value="-6.55" spread="7.04"/>
                    <measurement group_id="O4" value="-8.86" spread="7.35"/>
                    <measurement group_id="O5" value="-5.98" spread="6.63"/>
                    <measurement group_id="O6" value="-5.72" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 24-hour mean SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.28" spread="14.2"/>
                    <measurement group_id="O2" value="139.90" spread="15.87"/>
                    <measurement group_id="O3" value="144.30" spread="15.68"/>
                    <measurement group_id="O4" value="140.83" spread="11.23"/>
                    <measurement group_id="O5" value="141.28" spread="14.73"/>
                    <measurement group_id="O6" value="143.35" spread="17.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change in 24-hour mean SBP at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.54" spread="7.46"/>
                    <measurement group_id="O2" value="-3.16" spread="10.54"/>
                    <measurement group_id="O3" value="-7.72" spread="11.37"/>
                    <measurement group_id="O4" value="-9.23" spread="9.92"/>
                    <measurement group_id="O5" value="-6.07" spread="8.93"/>
                    <measurement group_id="O6" value="-7.23" spread="14.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)</title>
        <description>Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group.
The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5).
The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1).
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
        <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
        <population>All participants in a treatment group with a full set of ABPM (Ambulatory Blood Pressure Monitoring) values over the 24-hour period at baseline and at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)</title>
          <description>Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group.
The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5).
The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1).
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.</description>
          <population>All participants in a treatment group with a full set of ABPM (Ambulatory Blood Pressure Monitoring) values over the 24-hour period at baseline and at Week 8.</population>
          <units>Ratio of mean at trough to mean at peak</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.03"/>
                    <measurement group_id="O2" value="2.59"/>
                    <measurement group_id="O3" value="0.90"/>
                    <measurement group_id="O4" value="1.49"/>
                    <measurement group_id="O5" value="1.25"/>
                    <measurement group_id="O6" value="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</title>
        <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
        <time_frame>Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)</time_frame>
        <population>The Full Analysis Set (FAS) includes all participants randomized who had a baseline mean trough SiDBP. Participants were evaluated according to the study treatment they have been assigned to. Missing data was analyzed by LOCF (Last Observation Carried Forward).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aprocitentan 5 mg</title>
            <description>One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O3">
            <title>Aprocitentan 10 mg</title>
            <description>Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aprocitentan 25 mg</title>
            <description>One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O5">
            <title>Aprocitentan 50 mg</title>
            <description>One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.</description>
          </group>
          <group group_id="O6">
            <title>Lisinopril 20 mg</title>
            <description>One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan.</description>
          </group>
        </group_list>
        <measure>
          <title>Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough</title>
          <description>Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.</description>
          <population>The Full Analysis Set (FAS) includes all participants randomized who had a baseline mean trough SiDBP. Participants were evaluated according to the study treatment they have been assigned to. Missing data was analyzed by LOCF (Last Observation Carried Forward).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="77"/>
                <count group_id="O6" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="5.5"/>
                    <measurement group_id="O2" value="97.5" spread="5.3"/>
                    <measurement group_id="O3" value="97.7" spread="4.2"/>
                    <measurement group_id="O4" value="98.2" spread="5.0"/>
                    <measurement group_id="O5" value="98.4" spread="5.3"/>
                    <measurement group_id="O6" value="96.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="11.1"/>
                    <measurement group_id="O2" value="-5.8" spread="8.9"/>
                    <measurement group_id="O3" value="-9.9" spread="8.4"/>
                    <measurement group_id="O4" value="-11.7" spread="7.8"/>
                    <measurement group_id="O5" value="-9.9" spread="7.8"/>
                    <measurement group_id="O6" value="-8.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Multiple Comparison Procedure-Modeling (MCP-Mod) was used to assess a dose-response across placebo and all aprocitentan doses. The null hypothesis of &quot;no dose-response&quot; was rejected if at least one of the six Multiple Contrast Tests (MCTs) had a multiplicity adjusted p-value &lt;0.05. The analysis was performed using the R-package &quot;DoseFinding&quot; (Bornkamp B, Pinheiro J, Bretz F. Planning and analyzing dose finding experiments. 2016. Available from: cran.r-projects.org/web/packages/DoseFinding.)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Multiple Comparison Procedure-Modeling</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5356</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.401</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.19</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-5.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.396</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.25</ci_lower_limit>
            <ci_upper_limit>-2.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-7.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.96</ci_lower_limit>
            <ci_upper_limit>-4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>with Dunnett correction.</method_desc>
            <param_type>LS Mean</param_type>
            <param_value>-5.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.11</ci_lower_limit>
            <ci_upper_limit>-2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks after first intake of medication after randomization.</time_frame>
      <desc>The treatment-emergent adverse events were defined as those adverse events with onset on or after the first day of double-blind study treatment intake up to the last day of double-blind study treatment intake plus 30 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="E2">
          <title>Aprocitentan 5 mg</title>
          <description>Participants received aprocitentan 5 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="E3">
          <title>Aprocitentan 10 mg</title>
          <description>Participants received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="E4">
          <title>Aprocitentan 25 mg</title>
          <description>Participants received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="E5">
          <title>Aprocitentan 50 mg</title>
          <description>Participants received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
        <group group_id="E6">
          <title>Lisinopril 20 mg</title>
          <description>Participants received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lens disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Periorbital haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haematocrit increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Norovirus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition frequency decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mole excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Desk</name_or_title>
      <organization>Idorsia Pharmaceuticals Ltd</organization>
      <phone>+41 58 844 19 77</phone>
      <email>clinical-trials-disclosure@idorsia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

